Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 8/20 | 0.40 |
| ▸ | PIM1 | P11309 | 4/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101950 | 1.00 | PIK3CA (0.45) | PIK3CAMTOREGFRPIM1TYRO3 | |
| SCHEMBL23950712 | 0.92 | PIK3CA (0.41) | PIK3CAMTOREGFRPIM1TYRO3 | |
| SCHEMBL25463600 | 0.92 | PIK3CA (0.41) | PIK3CAMTOREGFRPIM1TYRO3 | |
| SCHEMBL23950919 | 0.89 | PIK3CA (0.39) | PIK3CAMTOREGFRPIM1TYRO3 | |
| SCHEMBL30101847 | 0.89 | PIK3CA (0.39) | PIK3CAMTOREGFRPIM1TYRO3 | |
| SCHEMBL23950541 | 0.88 | EGFR (0.41) | PIK3CAMTOREGFRPIM1IRAK1 | |
| SCHEMBL23925737 | 0.86 | PIK3CA (0.41) | PIK3CAMTOREGFRTYRO3MERTK | |
| SCHEMBL25463142 | 0.86 | PIK3CA (0.41) | PIK3CAMTOREGFRTYRO3MERTK | |
| SCHEMBL25463143 | 0.84 | PIK3CA (0.40) | PIK3CAMTOREGFRTYRO3MERTK | |
| SCHEMBL30102054 | 0.84 | PIK3CA (0.40) | PIK3CAMTOREGFRTYRO3MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2023-05-11 | — | — | US | disclosed |
| WO-2021210970-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | DONG-A ST CO., LTD. (KR) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147257-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | AHR, ARNT, AIPL1 | PIK3CA 1832/4885MTOR 2868/4885EGFR 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.